https://clinicaltrials.stanford.edu/trials/p/NCT01807598.html
Phase II Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis +/- AHNMD
Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.
phase iibrentuximab vedotin